Prospective Comparison of Saliva and Nasopharyngeal Swab Sampling for Mass Screening for COVID-19

Nacher, Mathieu; Mergeay-Fabre, Mayka; Blanchet, Denis; Benoit, Orelie; Pozl, Tristan; Mesphoule, Pauline; Sainte-Rose, Vincent; Vialette, Véronique; Toulet, Bruno; Moua, Aurélie; Saout, Mona; Simon, Stéphane; Guidarelli, Manon; Galindo, Muriel; Biche, Barbara; Faurous, William; Chaizemartin, Laurie; Fahrasmane, Aniza; Rochemont, Devi; Vignier, Nicolas; Vabret, Astrid; Demar, Magalie

Current testing for COVID-19 relies on reverse-transcriptase polymerase chain reaction from a nasopharyngeal swab specimen. Saliva samples have advantages regarding ease and painlessness of collection, which does not require trained staff and may allow self-sampling. We enrolled 776 persons at various field-testing sites and collected nasopharyngeal and pooled saliva samples. One hundred sixty two had a positive COVID-19 RT-PCR, 61% were mildly symptomatic and 39% asymptomatic. The sensitivity of RT-PCR on saliva samples vs. nasopharygeal swabs varied depending on the patient groups considered or on Ct thresholds. There were 10 (6.2%) patients with a positive saliva sample and a negative nasopharyngeal swab, all of whom had Ct values <25 for three genes. For symptomatic patients for whom the interval between symptoms onset and sampling was <10 days sensitivity was 77% but when excluding persons with isolated N gene positivity (54/162), sensitivity was 90%. In asymptomatic patients, the sensitivity was only 24%. When we looked at patients with Cts <30, sensitivity was 83 or 88.9% when considering two genes. The relatively good performance for patients with low Cts suggests that Saliva testing could be a useful and acceptable tool to identify infectious persons in mass screening contexts, a strategically important task for contact tracing and isolation in the community.